23:55 , Aug 22, 2019 |  BC Innovations  |  Tools & Techniques

Digital makes its mark on cognition

Digital biomarkers of cognitive decline could be the antidote to the slop in the subjective tests on which clinical neurology programs often hinge. With proof of concept established in small clinical trials and bigger readouts...
23:34 , Jul 25, 2019 |  BC Extra  |  Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

Livongo, Castle rise in first trading day  Livongo Health inc. (NASDAQ:LVGO) and Castle Biosciences Inc. (NASDAQ:CSTL) each posted gains in their first day of trading Thursday after pricing upsized IPOs. Digital health play Livongo added...
12:31 , Jun 13, 2019 |  BioCentury  |  Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
18:42 , Jun 3, 2019 |  BioCentury  |  Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
20:52 , May 30, 2019 |  BC Extra  |  Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

Decrease in mortality from melanoma attributed to checkpoint inhibitors  The rate of death due to melanoma of the skin declined by 8.5% per year during 2014-16 among men and 6.3% per year in 2013-16 among...
10:44 , Apr 8, 2019 |  BC Extra  |  Financial News

Itch company Trevi files for IPO

With a Phase IIb/III study of pruritus therapy nalbuphine ER scheduled to read out next year, Trevi Therapeutics Inc. (New Haven, Conn.) is seeking to raise up to $86.3 million in an IPO. The company's...
17:51 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

BlackThorn deprioritizing MDD compound after Phase IIa miss

BlackThorn Therapeutics Inc. (San Francisco, Calif.) said it will deprioritize development of BTRX-246040 (formerly LY-2940094) to treat major depressive disorder (MDD) after the compound missed the primary and secondary endpoints in a Phase IIa trial....
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

BlackThorn licenses Yale's neuroimaging tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
23:38 , Aug 6, 2018 |  BC Extra  |  Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...